NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Sagimet Biosciences Inc. (SGMT) Stock Analysis

Sagimet Biosciences Inc. (SGMT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

SGMT

$10.94

+$0.02 (+0.18%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SGMT with… →

SGMT Key Statistics

As of Sep 4, 2026
Trading
Open
$10.79
Previous Close
$10.92
Day's Range
10.53–10.98
52-Week Range
4.50–11.24
Volume
1.25M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
3.49
Valuation
Market Cap
$680.02M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.26
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$51.04M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
61.59M
1-Year Return
+50.90%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
1.25M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SGMT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+84.80%
2025+31.56%
2024−16.97%
2023 (partial year)−66.02%

As of September 4, 2026.

SGMT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$51.04M—
2024$0.00−$45.57M—
2023$2.00M−$27.88M−1393.8%
2022$0.00−$30.50M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$56.89M−$51.04M—
2024$0.00—−$54.45M−$45.57M—
2023$2.00M—−$30.74M−$27.88M−1393.8%
2022$0.00—−$31.06M−$30.50M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SGMT Valuation vs Biotechnology Median

Median of 656 stocks
MetricSGMTBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Sagimet Biosciences Inc. (SGMT) carries a market capitalisation of $680.02M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 16 employees.

The most recent close on file for SGMT is $10.94, dated September 4, 2026. That is +$0.02 (+0.18%) against the previous close. The 52-week range on file runs from $4.50 to $11.24. The latest close sits 143.11% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $51.04M. The reported profit margin is 0%. Trailing earnings per share are −1.26.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 3.49. Annualized volatility over the trailing 3 years is 149.22%. The trailing one-year price return is +50.90%. Across 3 years the annualized return works out at −3.04%.

Growth & Income

No dividend is on file for SGMT.

The strongest complete calendar year on file is 2025 at +31.56%; the weakest is 2024 at −16.97%. So far in 2026 the price is +84.80%.

Peer Comparison

Sagimet Biosciences Inc. (SGMT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Sagimet Biosciences Inc. SGMT $680.02M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Sagimet Biosciences Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Sagimet Biosciences Inc.

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Visit website →